C
Constantinos Koumenis
Researcher at University of Pennsylvania
Publications - 156
Citations - 15751
Constantinos Koumenis is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Unfolded protein response & Tumor microenvironment. The author has an hindex of 52, co-authored 129 publications receiving 13837 citations. Previous affiliations of Constantinos Koumenis include Wake Forest University & Wake Forest Baptist Medical Center.
Papers
More filters
Journal ArticleDOI
Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways
Diane Fels,Jiangbin Ye,Andrew T. Segan,Steven J. Kridel,Michael T. Spiotto,Michael R. Olson,Albert C. Koong,Constantinos Koumenis +7 more
TL;DR: The results show that hypoxic tumor cells, which are generally more resistant to genotoxic agents, are hypersensitive to proteasome inhibitors and suggest that combining bortezomib with therapies that target the normoxic fraction of human tumors can lead to more effective tumor control.
Journal ArticleDOI
ATF4, an ER stress and hypoxia-inducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis.
TL;DR: The functional activation of ATF4 under hypoxia and the overexpression of ATF 4 in hypoxic areas of clinical samples of human tumors suggest that ATF4 plays a role in tumor hypoxic adaptation.
Journal ArticleDOI
Pancreatic cancer cells express 25-hydroxyvitamin D-1α-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3
Gary G. Schwartz,Dawn Eads,Anuradha Rao,Scott D. Cramer,Mark C. Willingham,Tai C. Chen,Daniel P. Jamieson,Lilin Wang,Kerry L. Burnstein,Michael F. Holick,Constantinos Koumenis +10 more
TL;DR: The expression of 1 alpha(OH)ase in normal and malignant pancreatic tissue and the antiproliferative effects of the prohormone in these cells, suggest that 25( OH)D(3) may offer possible therapeutic and chemopreventive options for pancreatic cancer.
Journal ArticleDOI
Development of a stress response therapy targeting aggressive prostate cancer.
Hao G. Nguyen,Crystal S. Conn,Yae Kye,Lingru Xue,Craig M. Forester,Janet E. Cowan,Andrew C. Hsieh,John T. Cunningham,Charles Truillet,Feven Tameire,Michael J. Evans,Christopher P. Evans,Joy C. Yang,Byron Hann,Constantinos Koumenis,Peter Walter,Peter R. Carroll,Davide Ruggero +17 more
TL;DR: Using murine and humanized models of prostate cancer (PCa), it is shown that one of the three branches of the unfolded protein response is selectively activated in advanced PCa and selectively triggers cytotoxicity against aggressive metastatic PCa.
Journal ArticleDOI
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.
Angelica Ortiz,Jun Gui,Farima Zahedi,Pengfei Yu,Christina Cho,Sabyasachi Bhattacharya,Christopher J. Carbone,Qiujing Yu,Kanstantsin V. Katlinski,Yuliya V. Katlinskaya,Simran Handa,Victor Haas,Susan W. Volk,Angela K Brice,Kim Wals,Nicholas J Matheson,Robin Antrobus,Sonja Ludwig,Sonja Ludwig,Theresa L. Whiteside,Cindy Sander,Ahmad A. Tarhini,John M. Kirkwood,Paul J. Lehner,Wei Guo,Hallgeir Rui,Andy J. Minn,Constantinos Koumenis,J. Alan Diehl,Serge Y. Fuchs +29 more
TL;DR: The finding that melanoma TEV downregulated type I interferon receptor and expression of IFN-inducible cholesterol 25-hydroxylase (CH25H) suggests the importance of CH25H in defense against education of normal cells by TEV and argues for the use of reserpine in adjuvant melanoma therapy.